280 related articles for article (PubMed ID: 17189063)
1. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer.
Zelefsky MJ; Yamada Y; Cohen GN; Shippy A; Chan H; Fridman D; Zaider M
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):65-70. PubMed ID: 17189063
[TBL] [Abstract][Full Text] [Related]
2. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
[TBL] [Abstract][Full Text] [Related]
3. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
[TBL] [Abstract][Full Text] [Related]
4. Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging.
Zelefsky MJ; Cohen G; Zakian KL; Dyke J; Koutcher JA; Hricak H; Schwartz L; Zaider M
Cancer J; 2000; 6(4):249-55. PubMed ID: 11038145
[TBL] [Abstract][Full Text] [Related]
5. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
Zelefsky MJ; Chan H; Hunt M; Yamada Y; Shippy AM; Amols H
J Urol; 2006 Oct; 176(4 Pt 1):1415-9. PubMed ID: 16952647
[TBL] [Abstract][Full Text] [Related]
7. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
[TBL] [Abstract][Full Text] [Related]
8. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
[TBL] [Abstract][Full Text] [Related]
9. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
10. [Permanent implant brachytherapy for early, organ-confined prostate cancer].
Agoston P; Major T; Fröhlich G; Baricza K; Szabó Z; Lövey J; Varjas G; Kásler M; Fodor J; Polgár C
Magy Onkol; 2011 Sep; 55(3):170-7. PubMed ID: 21918742
[TBL] [Abstract][Full Text] [Related]
11. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
[TBL] [Abstract][Full Text] [Related]
12. Initial comparison of inverse optimization, modified peripheral technique, and geometric optimization as real-time intraoperative computer planning options for permanent seed implantation of the prostate.
Raben A; Sammons S; Sim S; Chen H; Hanlon A; Sarkar A; Donavanik V; Grebler A; Geltzeiler J; Benge B; Glick A; Jacob D; Koprowski P
Brachytherapy; 2007; 6(4):238-45. PubMed ID: 17991621
[TBL] [Abstract][Full Text] [Related]
13. Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.
Zaider M; Zelefsky MJ; Cohen GN; Chui CS; Yorke ED; Ben-Porat L; Happersett L
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):702-13. PubMed ID: 15708248
[TBL] [Abstract][Full Text] [Related]
14. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy.
Zelefsky MJ; Yamada Y; Marion C; Sim S; Cohen G; Ben-Porat L; Silvern D; Zaider M
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):956-63. PubMed ID: 12605973
[TBL] [Abstract][Full Text] [Related]
15. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
[TBL] [Abstract][Full Text] [Related]
17. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
[TBL] [Abstract][Full Text] [Related]
18. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
[TBL] [Abstract][Full Text] [Related]
19. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy.
Jereczek-Fossa BA; Zerini D; Vavassori A; Fodor C; Santoro L; Minissale A; Cambria R; Cattani F; Garibaldi C; Serafini F; Matei VD; de Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):115-25. PubMed ID: 19004572
[TBL] [Abstract][Full Text] [Related]
20. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]